Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Beam Therapeutics's Enterprise Value is $1,932.8 Mil.
Beam Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-369.7 Mil. Therefore, Beam Therapeutics's EV-to-OCF for today is -5.23.
The historical rank and industry rank for Beam Therapeutics's EV-to-OCF or its related term are showing as below:
BEAM'
s EV-to-OCF Range Over the Past 10 Years
Min: -69.39 Med: -4.61 Max: 112.33
Current: -5.38
During the past 9 years, the highest EV-to-OCF of Beam Therapeutics was 112.33. The lowest was -69.39. And the median was -4.61.
BEAM's EV-to-OCF is ranked better than 57.91% of 1409
companies
in the Biotechnology industry
Industry Median: -3.48
vs BEAM: -5.38
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Beam Therapeutics's PE Ratio (TTM) for today is calculated as:
Beam Therapeutics's share price for today is $27.48.
Beam Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.860.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Beam Therapeutics EV-to-OCF Related Terms
Beam Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Beam Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Beam Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beam Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beam Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Beam Therapeutics's EV-to-OCF falls into.
Beam Therapeutics's current Enterprise Value is $1,932.8 Mil.
Beam Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-369.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beam Therapeutics (BEAM) has a EV-to-OCF of -5.23 as of Aug. 07, 2026. According to the industry distribution chart, Beam Therapeutics ranks #593 out of 1409 companies in the Biotechnology industry, placing it in the top 42.1%.
Is Beam Therapeutics' EV-to-OCF too high?
Beam Therapeutics' current EV-to-OCF is -5.23. Based on the distribution chart, Beam Therapeutics ranks #593 out of 1409 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Beam Therapeutics has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' EV-to-OCF compare to KOD and TARS?
According to the Biotechnology industry distribution chart, Beam Therapeutics ranks #593 out of 1409 companies for EV-to-OCF. This puts Beam Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Beam Therapeutics's current EV-to-OCF is -5.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (BEAM) is currently considered Fairly Valued. The stock's GF Value™ is $28.11, compared to a current price of $27.48 — trading 2.2% below its estimated fair value. The current EV-to-OCF is -5.23. Beam Therapeutics' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Beam Therapeutics (BEAM), the current EV-to-OCF is -5.23 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beam Therapeutics (BEAM) Overvalued in 2026?
Based on GuruFocus' analysis, Beam Therapeutics stock appears to be undervalued.
The current stock price of $27.48 is trading 2.2% below its estimated GF Value™ of $28.11.
GuruFocus considers Beam Therapeutics to be Fairly Valued.
Key valuation signals for BEAM:
EV-to-OCF: -5.23
GF Value™: $28.11 vs. price of $27.48 (2.2% below fair value)
No single metric tells the full story. See the BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
71GF Score
Get the complete analysis for BEAM
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BEAM has been successfully added to your 
